The FDA's commitment to a fast-track review and recognition of the drug shortage significantly de-risks the remaining packaging deficiency. Traders should watch for the company's submission of manufacturer certifications and any subsequent FDA approval announcement. Approval could unlock a new revenue stream for NRx in a market with limited U.S.-based supply.
Drug in focus
NRXP drug pipeline →Preservative-Free Ketamine
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (ANDA)
- Time to market
- Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
- Next catalyst
- None dated
What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 7 $3.58entry
- T+1 · 3mo ago −6.42%α −6.39% · $3.35
- T+5 · 3mo ago −8.66%α −9.06% · $3.27
- T+20 · 2mo ago −2.51%α −2.12% · $3.49
- T+60 · 15d ago −38.69%α −36.55% · $2.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals disclosed that the FDA completed first-round review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, but identified a single major deficiency related to the vial's luer lock cap. The FDA committed to reinitiate review in the shortest possible cycle, citing ketamine's status on the drug shortage list. Management expects first commercial sales in 2026 if the packaging issue is resolved.
Key Facts
- ANDA for preservative-free ketamine filed September 2025
- FDA advised July 30, 2026: no major drug-related deficiencies on first-round review
- One major deficiency identified: twist-off cap of luer lock vial (container closure concern)
- Clarification meeting held August 6, 2026 with FDA Office of Generic Drugs and CDER leadership
- FDA committed to immediately reinitiate review and complete in shortest-possible cycle
- Ketamine is on the current FDA drug shortage list and recognized as a strategic drug
- Management estimates only 14%-18% of ANDAs achieve approval on first-round review
- Company provided data: 11.9 million doses of similar vials shipped in past 12 months without complaints, returns, or recalls
Financial Impact
No financial figures provided; potential revenue from first-to-market generic preservative-free ketamine in the U.S. if approved
Risk Factors
- FDA may not accept the manufacturer certifications or may require additional data
- Resolution of the vial cap deficiency could take longer than anticipated, delaying first commercial sales beyond 2026
- Competition from other ANDA filers for preservative-free ketamine could erode market opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-026428 |
| Document: 0001437749-26-026428-index-headers.html | 0001437749-26-026428 |
| Document: 0001437749-26-026428-index.html | 0001437749-26-026428 |
| Document: 0001437749-26-026428.txt | 0001437749-26-026428 |
Track record
22 reports on NRXP
8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers